A comparative study of the efficacy and safety of Hemoforce Family in the treatment of iron deficiency anaemia in a tertiary healthcare facility in Northern Ghana.

Shalina Healthcare0 sites200 target enrollmentSeptember 21, 2022

Overview

No summary available.

Registry

who.int

Start Date

September 21, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Shalina Healthcare

•Male or female (\=12 years) suffering from iron deficiency anaemia having hemoglobin between 9 to 12 g/dl.
•Patients or parents willing to provide written informed consent to use personal and/or health data prior to the entry into the study.

•Anaemia not linked to iron deficiency.
•Hemoglobin less than 9 g/dL.
•Allergy to iron derivatives.
•Any medical disorder like diabetes or tuberculosis (TB), viral hepatitis cirrhosis, renal disease, autoimmune disease.
•Those who had received parenteral iron treatment earlier within 3 months before the start of the study.
•Patients with history of chronic blood loss.
•Alcohol abuse within past 6 months.
•Hemosiderosis, hemochromatosis or other iron storage disorders.
•Patients with a history or present illness that is a malignant tumor or autoimmune disease.
•Patients who underwent oral administration of an iron preparation (including an over\-the\-counter drug or supplement) within 4 weeks before the screening.